Comparative effectiveness of the sodium–glucose cotransporter 2 inhibitor empagliflozin versus other antihyperglycemics on risk of major adverse kidney events
Dive into the research topics of 'Comparative effectiveness of the sodium–glucose cotransporter 2 inhibitor empagliflozin versus other antihyperglycemics on risk of major adverse kidney events'. Together they form a unique fingerprint.